| Project/Area Number |
25460049
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KASE Masahiko 関西医科大学, 医学部, 講師 (10309221)
TRIFONOV Stefan 関西医科大学, 医学部, 助教 (30598173)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SAKURAI Fuminori 大阪大学, 薬学部, 准教授 (70370939)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 癌幹細胞 / グリオーマ / 遺伝子発現解析 / スフェロイド |
|---|
| Outline of Final Research Achievements |
Gliomas are most common type of brain tumor and malignant gliomas have high recurrence rates and poor prognosis. In recent years, cancer stem cells are considered to be a cause of metastasis and recurrence after treatment. Since past therapeutic strategy against glioma targets whole tumor cells, these strategy are not effective for cancer stem cells which shows resistant to therapy. Here, we established human glioma stem cell lines and constructed molecular basis to specifically express therapeutic genes in glioma stem cells.
|
